| abstract |
A novel combination comprising: a B-Raf inhibitor, especially N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1 ,3‑thiazol‑4‑yl]‑2‑fluorophenyl}‑2,6‑difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and/or the MEK inhibitor N‑{3‑[3‑cyclopropane Base-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido [4,3-d]pyrimidin-1-yl]phenyl}acetamide or a pharmaceutically acceptable salt or solvate thereof, and panitumumab (Vicotib); pharmaceutical compositions containing them and the use of such Such combinations and compositions treat conditions, such as cancer, that would benefit from inhibition of MEK and/or B-Raf and/or EGFR. |